SUN11031

Drug Name: SUN11031
Company: Daiichi Sanyo, Inc
Location: US-New Jersey
Website: http://www.dsi.com/home
Drug Type: Protein Biologic
Conditions: ALS
Mechanism Type: Promoting appetite (Cachexia)
Mechanism: SUN11031 is a peptide hormone that is a ghrelin receptor agonist (it is a synthetic form of ghrelin). In preclinical studies in the SOD1 models of ALS, ghrelin attenuated disease progression through orexigenic effects (promoting appetite), as well as by preventing muscle wasting and weight loss via non-oregigenic effects.
U.S. Status for ALS: Inactive

References:
[1] Ghrelin attenuates disease progression in a mouse model of amyotrophic lateral sclerosis. Matsuo, T et al. F1000Posters 2014, 5:29 (poster). Accessed 28 Dec 2015 from http://f1000research.com/posters/1094908.
[2] SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD). ClinicalTrials.gov, 19 Oct 2015. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT00698828.

Last updated December 28th, 2015

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail